This inventor holds 1 USPTO granted patent. Top assignee: Cansino Biologics Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Huihua Mao - Innovator in Adenovirus Production
Introduction
Huihua Mao is a notable inventor based in Tianjin, China. He has made significant contributions to the field of biotechnology, particularly in the production of adenoviruses. His innovative work focuses on enhancing the safety and efficiency of adenovirus production, which is crucial for vaccine development and other therapeutic applications.
Latest Patents
Huihua Mao holds a patent for a cell strain designed to reduce the production of replication competent adenovirus. The patent, titled "Cell strain for reducing production of replication competent adenovirus, and construction method and use thereof," describes the HEK293.CS cell strain. This cell line is engineered by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 cells. The resulting HEK293.CS cell line maintains its growth and virus production capabilities while eliminating the production of detectable replication competent adenovirus (RCA). This advancement allows for safer mass culture of recombinant human type 5 adenovirus, thereby minimizing the risk of RCA production during the manufacturing of vaccines and antibodies.
Career Highlights
Huihua Mao is currently associated with CanSino Biologics Inc., a company known for its innovative approaches in vaccine development. His work at CanSino has positioned him as a key player in the biotechnology sector, contributing to advancements that have the potential to impact public health positively.
Collaborations
Huihua has collaborated with notable colleagues, including Tao Zhu and Lei Duan. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of biotechnology.
Conclusion
Huihua Mao's contributions to adenovirus production exemplify the importance of innovation in biotechnology. His patented cell strain represents a significant step forward in ensuring the safety and efficacy of viral vector-based therapies. Through his work, he continues to influence the landscape of vaccine development and therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile